AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02841579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose.
Study NCT04406623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-172154
Description: The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Study NCT02775500 — intervention group
Intervention type: DRUG
Intervention: apremilast
Description: Comparison of women exposed during pregnancy versus women who are not exposed to apremilast
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perphenazine
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perphenazine
Study NCT00837265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Pegfilgrastim will be administered per dose and schedule specified in the arm description.
Study NCT04096170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV lidocaine
Description: Patients randomized to the IV lidocaine group will receive a 100 mg lidocaine bolus on induction then an infusion of 1.5 mg/kg/hr prior to incision. This infusion will continue throughout operation and into the PACU for 1 hour OR until the 2gm/250 mL D5W bag has been infused, whichever occurs first.
Study NCT04096170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: o Patients randomized to the placebo group will receive D5W solution (as this is the carrier for lidocaine) at the same volume and rate as the IV lidocaine.
Study NCT01965613 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Xilonix
Description: IV
Study NCT04065841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropifexor
Description: 100mcg+30mcg+10mcg capsules of tropifexor taken orally every day until the 140 mcg capsule of tropifexor taken orally every day is produced, then patients will switch to the single 140mcg capsule taken orally every day
Study NCT04065841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Licogliflozin
Description: 30mg tablet of licoglifozin taken orally every day
Study NCT04065841 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: licogliflozin placebo + tropifexor placebo
Study NCT04039347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Cyclosporine A 5 mg
Description: delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
Study NCT04039347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Cyclosporine A 10 mg
Description: delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
Study NCT00837265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Regimen
Description: The chemotherapy regimen consisting of doxorubicin 60 mg/square meter (m\^2) and docetaxel 75 mg/m\^2 will be administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.
Study NCT00837265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy Regimen
Description: The chemotherapy regimen consisting of doxorubicin 60 mg/square meter (m\^2) and docetaxel 75 mg/m\^2 will be administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.
Study NCT02533765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib dispensed to patients at the dose of 300 mg twice daily (BID) continuously until the patient completes the study, withdraws from the study or closure of the study.
Study NCT04621175 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EAA+W & Carbohydrate
Description: Essential amino acid plus whey beverage with added carbohydrate
Study NCT04621175 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EAA+W & EAA
Description: Essential amino acid plus whey beverage with added essential amino acid
Study NCT04893733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B Complex
Description: Patients with established AKI will be randomized to received IV vitamin B complex each 1 hours for 5 consecutive days versus placebo.~Every patients will also received Institution standard of care for AKI
Study NCT04893733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STOP AKI protocol
Description: STOP AKI protocols includes:~S: identify and treat sepsis. Standard measures should be followed to decrease the risk of infection. Close surveillance to identify early signs of infection with appropriate treatment T: avoid nephrotoxins. Avoidance of drugs harmful to the kidneys (e.g. NSAIDs, gentamicin) Care with intravenous iodinated contrast O: optimize blood pressure and optimize volume status. Avoid dehydration e.g. confused patient. Treat hypovolaemia promptly. Consider with-holding patient anti-hypertensives/diuretics until assessed after major surgery or if patient develops sepsis/hypovolemia P: Prevent harm. Identify the cause promptly and manage appropriately to prevent progression. Prevent complications by instituting prompt therapy. Identify drugs excreted through the kidneys and adjust drug doses promptly if AKI develops. Review fluid management plans to prevent inadequate or excessive intravenous fluid administration
Study NCT04050436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cemiplimab
Description: Cemiplimab administered intravenously
Study NCT04050436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab administered intravenously
Study NCT04050436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP1
Description: RP1 administered intratumorally
Study NCT05331053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Simvastation acts as a systemic LOX inhibitor.
Study NCT01751906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorb BVS
Description: * Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.~* The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.~Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Study NCT01751906 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE
Description: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).~* Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm~* Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition~* For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices~To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Study NCT04110951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pranayama Breathing Technique
Description: Yogic Breathing Technique
Study NCT04110951 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation technique
Description: Progressive relaxation technique
Study NCT04379479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dialyzable Leukocyte Extract
Description: Experimental Intervention. Dialyzable Leukocyte Extract
Study NCT04379479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral
Description: Placebo
Study NCT03827382 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention
Description: Physical activity program: 3-5 aerobic training sessions (15-40 minutes each) per week, combined with 2 resistance training per week as well as motivational coaching via telephone Nutritional counseling
Study NCT03470324 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: [standard STN]
Description: standard stimulation on subthalamic (STN) contacts High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
Study NCT03470324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: [STN+SNr]
Description: Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr) high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
Study NCT03470324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swallowing therapy
Description: Swallowing therapy with speech therapist
Study NCT03470324 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Swallowing therapy
Description: Swallowing therapy with speech therapist
Study NCT00328562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD1839 (Iressa)
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulpiride
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulpiride
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bromperidol
Study NCT04580446 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated intensity modulated radiotherapy
Description: Hypofractionated intensity modulated radiotherapy with concurrent chemotherapy (weekly cisplatin)
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bromperidol
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zuclopenthixol
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zuclopenthixol
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioridazine
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioridazine
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Study NCT00328562 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiotherapy
Study NCT00368381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Patients randomized to this arm will receive hydrocortisone for the treatment of adrenal insufficiency secondary to sepsis.
Study NCT01089413 — intervention group
Intervention type: DRUG
Intervention: bevacizumab [Avastin]
Description: As prescribed by physician
Study NCT04554693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Oral
Description: 250 mg oral three times a day for 14 days
Study NCT04554693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Halal and Kosher certified gelatin placebo capsules oral three times a day for 14 days
Study NCT01050504 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study NCT01480804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention for age specific barriers to self care
Description: The intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by care manager over 6 month period in person and by phone calls. During the six to twelve month period subjects did not have any contact with study staff or care manager.
Study NCT03277430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Live donor uterus transplantation
Description: Transplantation of uterus from a living donor.
Study NCT01050504 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03277430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deceased donor uterus transplantation
Description: Transplantation of uterus from a deceased brain-dead donor.
Study NCT03277430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Maintenance immunosuppression in UTx recipient will be reduced to tacrolimus monotherapy to minimalize fetal compromise.
Study NCT04204265 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Monovisc
Description: A chemically cross-linked sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe.
Study NCT01271010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants received cyclophosphamide 250 mg/m\^2 IV or 250 mg/m\^2 orally on Days 1-3 of each cycle.
Study NCT04324164 — intervention group
Intervention type: DRUG
Intervention: Third-generation EGFR-TKI
Description: Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.
Study NCT04324164 — intervention group
Intervention type: DRUG
Intervention: EGFR-TKI
Description: All EGFR-TKI
Study NCT02637479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GammaKnife®
Study NCT02637479 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 18F-2-fluoro-2-deoxy-D-glucose - positron emission tomography (FDG-PET)
Study NCT02637479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-2-fluoro-2-deoxy-D-glucose - positron emission tomography (FDG-PET)
Study NCT02637479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT03296371 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo saliva or buccal mucosa collection
Study NCT03296371 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03296371 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01427153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthopaedic manual physical therapy
Description: OMPT consists of joint and soft-tissue mobilizations and the exercises that reinforce the manual techniques.
Study NCT01427153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: Corticosteroid injection to the tibiofemoral joint
Study NCT03326713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling & Navigation (TCN)
Description: A health coach will conduct a 30-45 minute telephone counseling session with participants. Prior to the telephone session, participants will receive the same brochure that the TP arm receives. After the phone call, participants will receive a tailored follow-up letter which will include images tailored to the individual's age, self-identified ethnicity, and family composition.
Study NCT03326713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mailed Targeted Print (TP)
Description: Participants will be mailed an educational brochure within two weeks of completing the baseline survey that addresses important evidence-based theoretical targets: CGRA guideline (knowledge), threat appraisal (to validate or raise risk perceptions, HBOC seriousness), response efficacy (benefits and expectations about CGRA), self-efficacy messages (CGRA resources, insurance reimbursement, and assistance for those with financial challenges) and possible actions to take (make an appointment and discuss with provider). Both the targeted print and tailored intervention materials were developed using formative community engaged research methods.
Study NCT03326713 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care (UC)
Description: A usual care arm is included to assess CGRA uptake in the absence of intervention as well as priming from the surveys for the primary outcome analysis.
Study NCT04082650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: 4000IU per day
Study NCT04082650 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same doses with vitamin D
Study NCT03750331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ap'Telecare
Description: an internet application on a computer, tablet or smartphone
Study NCT03750331 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional schedule
Description: a group of renal transplant outpatients consulting their Transplant Centre following a traditional schedule
Study NCT00235404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent treatment
Description: Specialized care in preparing recharge to home
Study NCT00235404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Usual recharge directly from hospital to home
Study NCT01271010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Participants received fludarabine 25 mg/m\^2 IV or 40 mg/m\^2 orally on Days 1-3 of each cycle.
Study NCT01271010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants received 375 mg/m\^2 IV on Day 1 of Cycle 1, then 500 mg/m\^2 IV on Day 1 of each subsequent cycle.
Study NCT02592616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CON
Description: No exercise intervention.
Study NCT02592616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CW
Description: One hour of continuous walking on a treadmill.
Study NCT02592616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IW
Description: One hour of interval (repeated cycles of 3 minutes of fast and 3 minutes of slow) walking on treadmill.
Study NCT02258971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEA 2180 BR oral
Description: Oral solution
Study NCT02258971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEA 2180 BR infusion
Description: Solution for infusion to be reconstituted with isotonic saline
Study NCT01576146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Administered as an intravenous bolus three times a week at the end of each hemodialysis session at dosages up to a maximum of 15 mg.
Study NCT02926027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vascepa
Description: Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.
Study NCT02926027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02437630 — intervention group
Intervention type: PROCEDURE
Intervention: Oesophageal balloon to measure intra-thoracic pressure
Description: An oesophageal balloon will be inserted via a nostril after instillation of local anaesthetic and swallowed until the tip is in the lower third of the oesophagus. This will allow the intrathoracic pressure to be monitored via a pressure sensor attached to the oesophageal balloon catheter and placed next to the subject. This will allow us to observe the changes in oesophageal pressure during quiet breathing under a variety of applied positive pressure conditions.
Study NCT02437630 — intervention group
Intervention type: PROCEDURE
Intervention: Fibre-optic laryngoscopy
Description: A fibre-optic laryngoscope will be inserted through the opposite nostril to that used for the oesophageal balloon and placed with its tip abve the larynx where the laryngeal movement can be observed This will allow us to observe the changes in laryngeal aperture under a variety of applied positive pressure conditions.
Study NCT02437630 — intervention group
Intervention type: OTHER
Intervention: standard lung function tests
Description: These will be carried out in any subject who has not had lung function testing in the previous 6 weeks and will be carried out by a lung function physiologist from the institution in accordance with standard procedures for lung function testing